JAZZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Jazz Pharmaceuticals (JAZZ) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong growth prospects driven by its oncology pipeline, positive analyst sentiment, and solid financial performance. Despite neutral technical indicators, the long-term outlook remains favorable.
The MACD is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 53.411, and moving averages are converging, suggesting no clear trend. Key support and resistance levels are Pivot: 165.502, R1: 168.607, S1: 162.396, R2: 170.526, S2: 160.477. The stock is trading near its resistance levels in pre-market.
Positive Phase 3 HERIZON-GEA-01 data for Ziihera, with analysts projecting significant peak sales potential in oncology.
Multiple analysts have raised price targets, with a consensus Buy rating.
Strong Q3 2025 financial performance with revenue up 6.74% YoY, net income up 16.91% YoY, and EPS up 19.30% YoY.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
Gross margin dropped by 1.21% YoY in Q3
Stock trend analysis indicates a 60% chance of a -2.26% drop in the next day.
In Q3 2025, Jazz Pharmaceuticals reported revenue of $1.126 billion, up 6.74% YoY. Net income increased to $251.41 million, up 16.91% YoY, and EPS rose to $4.08, up 19.30% YoY. However, gross margin slightly declined to 73.6%, down 1.21% YoY.
Analysts are highly positive on JAZZ, with multiple firms raising price targets recently. Notable updates include TD Cowen raising the target to $220, BofA to $263, and Morgan Stanley to $225. Analysts highlight the strong potential of Ziihera in oncology and view the stock as undervalued despite recent pressure.
